Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies
Po‐Hong Liu, Teh–Ia Huo, Rebecca A. Miksad
Seminars in Liver Disease (2018) Vol. 38, Iss. 03, pp. 242-251
Closed Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients
Wenwen Zhang, Bingyang Hu, Jun Han, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 58
Rapid synthesis of a Bi@ZIF-8 composite nanomaterial as a near-infrared-II (NIR-II) photothermal agent for the low-temperature photothermal therapy of hepatocellular carcinoma
Jinghua Li, Daoming Zhu, Weijie Ma, et al.
Nanoscale (2020) Vol. 12, Iss. 32, pp. 17064-17073
Open Access | Times Cited: 54
The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Fangzhou Luo, Mengxia Li, Jun Ding, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 42
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review
Ziwen Tao, Baoquan Cheng, Tao Zhou, et al.
Hepatobiliary & pancreatic diseases international (2021) Vol. 21, Iss. 2, pp. 134-144
Closed Access | Times Cited: 42
Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
Xuqi Sun, Qi Zhang, Jie Mei, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 34
The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis
Qianyu Shi, Tao Ji, Xiaodong Tang, et al.
Cellular Oncology (2023) Vol. 46, Iss. 3, pp. 521-532
Closed Access | Times Cited: 17
Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Wenzhe Fan, Guosheng Yuan, Huishuang Fan, et al.
Clinical Therapeutics (2019) Vol. 41, Iss. 8, pp. 1463-1476
Closed Access | Times Cited: 45
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis
Miao Liu, Junyi Shi, Tong Mou, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 35, Iss. 8, pp. 1277-1287
Closed Access | Times Cited: 40
A New Tumor Burden Score and Albumin–Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma
Shu‐Yein Ho, Po‐Hong Liu, Chia-Yang Hsu, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 649-649
Open Access | Times Cited: 25
Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review
Wei Zhang, Deliang Ouyang, Zhangkan Huang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study
Xiaoquan Ji, Zhe Xu, Jing Sun, et al.
Radiation Oncology (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 13
Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Yue Hu, Min Zhou, Jing Tang, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 20, pp. 4088-4097
Closed Access | Times Cited: 13
Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
Qingyan Liu, Rong Li, Ling-ling LI, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
<p>Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study</p>
Guosheng Yuan, Xiao Cheng, Qi Li, et al.
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 12683-12693
Open Access | Times Cited: 34
Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Wei-Li Xia, Xiao-Hui Zhao, Yuan Guo, et al.
Clinical and Translational Gastroenterology (2023)
Open Access | Times Cited: 11
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
Jeayeon Park, Yun Bin Lee, Yunmi Ko, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 1, pp. 81-91
Open Access | Times Cited: 4
Direct contact between tumor cells and platelets initiates a FAK-dependent F3/TGF-β positive feedback loop that promotes tumor progression and EMT in osteosarcoma
Qianyu Shi, Jiuhui Xu, Chenglong Chen, et al.
Cancer Letters (2024) Vol. 591, pp. 216902-216902
Closed Access | Times Cited: 4
Clinical Significance of Acyl-CoA Dehydrogenase Short Chain and Its Anti-tumor Role in Hepatocellular Carcinoma by Inhibiting Canonical Wnt/β-Catenin Pathway
Jiawei Gu, Zhipeng Cao, Gengming Niu, et al.
Digestive Diseases and Sciences (2025)
Closed Access
Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis
Jeayeon Park, Su Jong Yu
The Ewha Medical Journal (2025) Vol. 48, Iss. 1
Open Access
Comparative analysis of hepatectomy for HCC with PVTT: insights from a 30-year single-center experience
Zhicheng Yao, Yupeng Ren, Mingbo Cao, et al.
Surgical Oncology (2025) Vol. 60, pp. 102211-102211
Closed Access
Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis
Xiaohui Wang, Changjun Liu, Hao‐quan Wen, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 3
Open Access | Times Cited: 10
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review
Suqi Zhu, Yahan Yu, Mingqi Yang, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 6, pp. 423-434
Closed Access | Times Cited: 3
Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection
Fuchen Liu, Xinggang Guo, Wei Dong, et al.
International Journal of Biological Sciences (2020) Vol. 16, Iss. 16, pp. 3210-3220
Open Access | Times Cited: 27
Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial
Beom Kyung Kim, Do Young Kim, Hwa Kyung Byun, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 107, Iss. 1, pp. 106-115
Closed Access | Times Cited: 24
Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathway
Ming-Da Wang, Nan-Ya Wang, Hui‐Lu Zhang, et al.
Oncogenesis (2021) Vol. 10, Iss. 11
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top